Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Dynavax Technologies Down 5.3%, Shares Slide into the Red (DVAX)
Comtex SmarTrend(R) - Tue Apr 15, 12:47PM CDT
Dynavax Technologies (NASDAQ
Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Tue Apr 15, 5:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013.
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/398z3d/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%. Out of the eight major markets the US, Canada, France, Germany, Italy, Spain, the UK and Japan the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively. The growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively. Christopher Pace, Ph.D., The report Analyst covering Infectious Diseases, says: Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine. However, the authors believe that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace. Pace says: In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults. For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period. This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022. Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Vaccination Recommendations and Coverage Rates Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Current and Future Players Market Outlook Appendix Companies Mentioned GSK Merck Sanofi Kaketsuken Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/39...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.
Scandal-Ridden SAC Capital Buys Broadcom, Dynavax, and Boston Scientific
Selena Maranjian, The Motley Fool - Motley Fool - Fri Mar 07, 4:44PM CST
The latest 13F season has arrived, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling....
Will Dynavax (DVAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:19AM CST
Will Dynavax (DVAX) Continue to Surge Higher?
Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.
Dynavax to receive USD5.4m milestone payment from AstraZeneca under the Phase 1 clinical study of AZD1419
M2 - Tue Mar 04, 7:06AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
Dynavax to Receive $5.4 Million Milestone
Marketwire - Mon Mar 03, 3:00PM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced a $5.4 million milestone payment from its collaborator, AstraZeneca. The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, following completion of the ongoing Phase 1 clinical study of AZD1419 for the treatment of asthma.
Dynavax to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Fri Feb 28, 3:00PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
SINA Q4 Makes More Money
SinoCast - Tue Feb 25, 4:21AM CST
SINA Corporation (Nasdaq: SINA) revealed net operating revenue of USD 197 million in fourth quarter ended December 31, 2013, rising 42% from a year earlier. Net profit reached USD 44.5 million, in contrast to USD 2.4 million a year earlier, representing USD 0.59 per share after being diluted, in contrast to USD 0.03 a year ago.